What is Acute Coronary Syndrome Treatment Market?

Acute Coronary Syndrome is an umbrella term that refers to a spectrum of conditions compatible with acute myocardial ischemia and/or infarction that are usually due to an abrupt reduction in coronary blood flow.

The traditional types of Acute Coronary Syndrome comprise of myocardial infarction with ST-segment elevation (STEMI), which generally reflects an acute total coronary occlusion, myocardial infarction without ST-segment elevation (NSTEMI), and unstable angina (UA), with or without myocardial injury, respectively.

DelveInsight's Acute Coronary Syndrome Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Acute Coronary Syndrome, historical and forecasted epidemiology as well as the Acute Coronary Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some facts of Acute Coronary Syndrome Market are:

• As per the results of Newmann et al. (2020), between 2005 and 2015, a total of 3797,546 cases of Acute Coronary Syndrome were recorded. The mean age was 69 years and 36% were females. From 2005 to 2015, the incidence rates of ACS, ST-elevation MI, and unstable angina pectoris decreased, while the incidence rate of non-ST-elevation MI increased. The percentages of performed coronary angiographies and percutaneous coronary interventions increased from 52% to 70% and 34 to 50%, respectively.
• According to a study conducted in Japan by Daida et al. (2013), ST-segment elevation myocardial infarction (STEMI) was the most frequent type of Acute Coronary Syndrome (59.4%). The vast majority (93.5%) of patients underwent percutaneous coronary intervention (PCI), with a success rate of 93.9%.
• According to available literature, males are affected more as compared to females, in the case of ACS.
• Gayle et al. (2017) stated that in 2014/15, there were 83,842 admissions to National Health Service hospitals in England and Wales, Northern Ireland, and Isle of Man with AMI as recorded in the UK national registry, Myocardial Ischaemia National Audit Project (MINAP). Of these, STEMI and NSTEMI comprised 40.5% and 59.5%, respectively. The ratio of STEMI to NSTEMI hospitalizations as recorded in MINAP has not changed over the last five years, from 1:1.50 in 2009/10 to 1:1.47 in 2014/15.

View Report: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market

Download Sample Report here: https://www.delveinsight.com/sample-request/acute-coronary-syndrome-market

Scope of Acute Coronary Syndrome Market are

• The report covers the descriptive overview of Acute Coronary Syndrome, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Acute Coronary Syndrome epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Acute Coronary Syndrome are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Acute Coronary Syndrome market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acute Coronary Syndrome market

View Report: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market

Request for Sample Report here: https://www.delveinsight.com/sample-request/acute-coronary-syndrome-market

Some of Acute Coronary Syndrome Companies are:

• Regeneron
• Sanofi
• DalCor Pharmaceutical
• CSL Behring
• AStraZeneca
• And Many Others

View Report: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market

Request for Free Sample Report here: https://www.delveinsight.com/sample-request/acute-coronary-syndrome-market

Acute Coronary Syndrome Therapies are:

• Alirocumab
• Dalcetrapib
• CSL112
• Brilinta
• And Many Others

Table of Contents:

1. Key Insights
2. Executive Summary of Acute Coronary Syndrome
3. Competitive Intelligence Analysis for Acute Coronary Syndrome
4. Acute Coronary Syndrome: Market Overview at a Glance

4.1. Acute Coronary Syndrome Total Market Share (%) Distribution in 2018

4.2. Acute Coronary Syndrome Total Market Share (%) Distribution in 2030

5. Acute Coronary Syndrome: Disease Background and Overview
6. Patient Journey
7. Acute Coronary Syndrome Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Acute Coronary Syndrome Treatment
11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Acute Coronary Syndrome: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Acute Coronary Syndrome
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Related Reports:

• Thymic Carcinoma Market
• Asphyxia Market
• Acute Agitation And Aggression Market
• HPV-Induced Cancers Market
• Diagnostic Imaging Equipment Market
• Epilepsy Market
• Defibrillators Market

About Delveinsight: 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Know More about our competitive intelligence services.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact

 Company Name: DelveInsight Business Research LLP

 Contact Person: Ankit Nigam

 Email: [email protected]

 Phone: +19193216187

 City: Albany

 State: New York

 Country: United States

 Website: https://www.delveinsight.com/